MX2022011064A - Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana. - Google Patents

Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana.

Info

Publication number
MX2022011064A
MX2022011064A MX2022011064A MX2022011064A MX2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A
Authority
MX
Mexico
Prior art keywords
incidence
human milk
methods
milk oligosaccharides
toddlers
Prior art date
Application number
MX2022011064A
Other languages
English (en)
Inventor
Steven R Davis
Rachael Buck
Geralyn O Duska-Mcewen
Jomay Chow
Hawley K Linke
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2022011064A publication Critical patent/MX2022011064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pediatric Medicine (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)

Abstract

Se describen los métodos para reducir la incidencia de la enterocolitis necrotizante en un bebé, un infante, o un niño al usar las composiciones nutricionales que incluyen los oligosacáridos de leche humana. Las composiciones nutricionales que incluyen los oligosacáridos de leche humana son eficaces en la reducción de la inflamación y de la incidencia de las enfermedades inflamatorias.
MX2022011064A 2010-12-31 2013-06-28 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana. MX2022011064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428863P 2010-12-31 2010-12-31
US201061428868P 2010-12-31 2010-12-31

Publications (1)

Publication Number Publication Date
MX2022011064A true MX2022011064A (es) 2022-10-07

Family

ID=45509697

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013007692A MX2013007692A (es) 2010-12-31 2011-12-22 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.
MX2022011064A MX2022011064A (es) 2010-12-31 2013-06-28 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana.
MX2020010780A MX2020010780A (es) 2010-12-31 2013-06-28 Métodos para disminuir la incidencia de la enterocolitis necrotizante en bebés, infantes, o niños al usar los oligosacáridos de leche humana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013007692A MX2013007692A (es) 2010-12-31 2011-12-22 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010780A MX2020010780A (es) 2010-12-31 2013-06-28 Métodos para disminuir la incidencia de la enterocolitis necrotizante en bebés, infantes, o niños al usar los oligosacáridos de leche humana.

Country Status (10)

Country Link
US (5) US9539269B2 (es)
EP (1) EP2658547A1 (es)
CN (1) CN107019701B (es)
BR (1) BR112013016905A2 (es)
CA (1) CA2822219C (es)
MX (3) MX2013007692A (es)
MY (2) MY197622A (es)
NZ (1) NZ611807A (es)
SG (3) SG10201603856PA (es)
WO (1) WO2012092156A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012092086A1 (en) 2010-12-29 2012-07-05 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EP2734210B1 (en) 2011-07-22 2017-11-22 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MY169326A (en) 2011-08-29 2019-03-21 Abbott Lab Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2013154725A1 (en) * 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
EP2708147B1 (en) * 2012-09-14 2020-03-11 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
FR2997819B1 (fr) * 2012-11-14 2015-06-26 Roquette Freres Utilisation de polysaccharides dans le bien etre intestinal du nourisson et/ou du jeune enfant
DK2934189T3 (da) 2012-12-18 2019-11-25 Abbott Lab Humane mælkeoligosaccharider til reduktion af stress-symptomer
WO2014100022A1 (en) * 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
TWI673052B (zh) * 2012-12-20 2019-10-01 美商亞培公司 使用人乳寡糖之用於調節炎症之營養調配物
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
WO2014138304A1 (en) 2013-03-08 2014-09-12 Axiom Foods, Inc., Rice protein supplements
US9352020B2 (en) * 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
MX2013003636A (es) * 2013-03-27 2014-09-29 Palsgaard Ind De Mexico S De R L De C V Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad.
US11135232B2 (en) * 2013-11-15 2021-10-05 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
CN105722514A (zh) 2013-11-15 2016-06-29 雀巢产品技术援助有限公司 用于预防或治疗剖腹产婴儿或幼儿的坏死性小肠结肠炎的组合物
AU2014350158A1 (en) * 2013-11-15 2016-04-14 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
WO2015077233A1 (en) * 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
US10792294B2 (en) 2014-04-08 2020-10-06 Abbott Laboratories Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
BR112017003920A2 (pt) 2014-09-25 2017-12-12 Nestec Sa sistema de fórmulas infantis para lactentes com teores adaptativos de oligossacarídeos de leite humano (hmos)
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160346303A1 (en) 2014-10-29 2016-12-01 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
PL3212198T3 (pl) * 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
AU2015340652B9 (en) * 2014-10-31 2020-04-16 Société des Produits Nestlé S.A. Composition comprising Fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
CN106998775A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 具有RRR‑α‑生育酚、2’‑岩藻糖基乳糖和益生菌的婴儿配方
ES2960750T3 (es) * 2015-03-05 2024-03-06 Glycom As Oligosacáridos de la leche humana para el tratamiento de infecciones agudas del aparato respiratorio
RU2720201C2 (ru) * 2015-03-05 2020-04-27 Сосьете Де Продюи Нестле С.А. Композиции для применения в профилактике или лечении отита или бронхита у младенцев или детей младшего возраста
US10709721B2 (en) * 2015-03-05 2020-07-14 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
CN107846957A (zh) * 2015-03-05 2018-03-27 雀巢产品技术援助有限公司 用于改善婴儿或幼儿粪便稠度或频率的组合物
AU2016303000B2 (en) 2015-08-04 2021-01-21 Société des Produits Nestlé S.A. Nutritional compositions with 2FL and LNnT for use in inducing a gut microbiota close to the one of breast fed infants
WO2017198276A1 (en) * 2016-05-19 2017-11-23 Glycom A/S Synthetic composition
CA3029631A1 (en) * 2016-07-01 2018-01-04 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system
EP3493817A1 (en) * 2016-08-04 2019-06-12 Nestec S.A. Nutritional compositions with 2fl and lnnt for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
US20180064739A1 (en) * 2016-09-06 2018-03-08 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
WO2018067923A1 (en) * 2016-10-06 2018-04-12 Tallgrass Therapeutics, Llc Compositions and methods for the prevention and treatment of colitis in infants
CN110868870A (zh) 2017-05-12 2020-03-06 艾斯姆食品公司 大米产物及制备它们的系统和方法
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
EP3630123A4 (en) * 2017-05-24 2020-10-28 Glycom A/S SYNTHETIC COMPOSITION WITH ONE OR MORE HUMAN MILK OLIGOSACCHARIDES (HMOS)
RU2740156C1 (ru) 2017-06-21 2021-01-12 Эбботт Лабораториз Способы улучшения роста полезных бактерий в желудочно-кишечном тракте
WO2019008105A1 (en) * 2017-07-07 2019-01-10 Nestec S.A. FORTIFYING HUMAN MILK
AU2018295414A1 (en) * 2017-07-07 2020-01-16 Societe Des Produits Nestle S.A. Human milk fortifier
CN107467677A (zh) * 2017-08-22 2017-12-15 北京特食生物科技研究中心（有限合伙） 一种润肠通便、维持肠道健康的复合营养品及其制备方法与应用
US20200246401A1 (en) * 2017-10-04 2020-08-06 Asian Institute Of Public Health Pharmaceutical composition comprising a probiotic and prebiotic to prevent acquisition of or treat drug resistant infections
WO2019106618A1 (en) 2017-11-30 2019-06-06 Glycom A/S Mixture of hmos for treating wheat sensitivity
AU2018387291A1 (en) * 2017-12-21 2020-05-07 Societe Des Produits Nestle S.A. Compositions for use in the promotion of intestinal muscle growth and development and associated intestinal motility
GB2573539A (en) * 2018-05-09 2019-11-13 Mjn Us Holdings Llc Wellbeing supplement for postpartum maternal nutrition
CN111248289B (zh) * 2018-11-30 2023-04-07 内蒙古伊利实业集团股份有限公司 一种组合物、其制备方法及用途
WO2020159357A1 (en) 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection
CA3130834A1 (en) 2019-02-22 2020-08-27 Aquero Canada Ltd. Fortified milk compositions and their processes of preparation
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物
US20240307338A1 (en) * 2021-01-27 2024-09-19 Sichuan Jiuzhang Biological Science And Technology Co., Ltd. Use of pharmaceutical composition containing chlorogenic acid in preparation of medicament for treating pathologic jaundice
CN113273695B (zh) * 2021-06-03 2022-05-17 海普诺凯营养品有限公司 一种改善新生儿溶血性高胆红素血症的组合物

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762822A (en) 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
JPH03266255A (ja) 1990-03-15 1991-11-27 Canon Inc オートチェンジャ
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
SE468536B (sv) 1991-07-03 1993-02-01 Bolin Mauritz Ingf Ab Stickkontakt
DE69530910D1 (de) 1994-07-15 2003-07-03 Taiyo Kagaku Co Medizinische zusammensetzungen enthaltend ein sialinsäurederivat
JPH08266255A (ja) 1995-03-30 1996-10-15 Taiyo Kagaku Co Ltd 学習能力向上組成物
WO1997048388A1 (en) 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
JP3552856B2 (ja) 1996-09-27 2004-08-11 雪印乳業株式会社 栄養強化組成物
DE19701382A1 (de) 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
ID22744A (id) 1997-02-21 1999-12-09 Abbott Lab Cs Metoda dan komposisi untuk mengurangi pengaruh dari nekrotisasi enterkolitis
SA98190002B1 (ar) 1997-03-28 2006-06-20 ذي يونيفيرسيتي اوف تننيسي ريسيرش كوربوريشن استخدام أحماض دهنية تحتوي على عدة روابط غير مشبعة polyunsaturated fatty acids لتقليل حدوث الالتهاب المعوي القولوني الناخر incidence of necrotizing enterocolitis
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US5906982A (en) 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
JPH10327804A (ja) 1997-06-04 1998-12-15 Meiji Milk Prod Co Ltd 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6294206B1 (en) 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6497908B1 (en) 1999-07-19 2002-12-24 Seiri Oshiro Turmeric-containing cooking oils and fats
DE19958985A1 (de) 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharidmischung
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
ATE357854T1 (de) 2000-02-17 2007-04-15 Wyeth Corp Prebiotische substanzen enthaltende ernährungszusammensetzungen
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
US7090862B2 (en) 2001-03-30 2006-08-15 Abbott Laboratories Method of improving the antioxidant status of an infant
WO2003003981A2 (en) 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
DE10147100A1 (de) 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
DE10204000A1 (de) 2002-02-01 2003-08-14 Nutricia Nv Sialysierte Kohlenhydrate
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
AR039170A1 (es) 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
AU2003282494A1 (en) 2002-10-11 2004-05-04 Wyeth Nutritional formulations containing synbiotic substances
FI20021989A0 (fi) 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
AU2002352938B8 (en) 2002-11-26 2009-10-08 The University Of Chicago Materials and methods for preventing and treating microbe-mediated epithelial disorders
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
US7951410B2 (en) 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
PT1638416E (pt) 2003-06-23 2013-07-08 Nestec Sa Utilização de uma fórmula nutricional para função de barreira intestinal óptima
WO2005000040A1 (en) 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
US7893041B2 (en) * 2003-12-05 2011-02-22 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
US20060039954A1 (en) 2003-12-23 2006-02-23 Gierhart Dennis L Ocular formulations with neuroprotectants to reduce Alzheimer and neurotoxic risks created by large zinc dosages
US7416752B2 (en) 2004-01-06 2008-08-26 Sharp Ingrained Functional Foods, Inc. Method of fortifying seeds with an essential fatty acid, fortified seed and food product
ES1056525Y (es) 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
US7851451B2 (en) 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
US7090879B2 (en) 2004-03-18 2006-08-15 Abbott Laboratories Nutritional formula containing select carotenoid combinations
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
DK1758469T4 (da) 2004-06-22 2013-11-04 Nutricia Nv Forbedring af barriereintegriteten hos HIV-patienter ved anvendelse af fedtsyrer
EP1721611A1 (en) 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
FR2872047B1 (fr) 2004-06-23 2007-06-15 Oreal Composition pour peaux sensibles associant cation mineral et probiotique(s)
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
EP1865795A1 (en) 2005-04-08 2007-12-19 Alimentary Health Limited Methods of use of orally administered probiotic bifidobacteria for human beauty benefits
US20060270739A1 (en) 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
US20060247153A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
US20060246146A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of increasing the salivary sialic acid content in a mammal
US9179702B2 (en) 2005-07-13 2015-11-10 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
EP1764934B1 (en) 2005-09-15 2022-03-30 Huawei Technologies Co., Ltd. Method for generating a frame in an orthogonal frequency division multiple access communication system
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
DK1951060T3 (da) 2005-11-04 2018-01-29 Arla Foods Amba Koncentrat afledt af et mælkeprodukt beriget med naturligt forekommende sialyllactose og en fremgangsmåde til fremstilling deraf
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
JP2009523173A (ja) 2006-01-09 2009-06-18 チルドレンズ ホスピタル メディカル センター 様々な病気の治療用のアディポネクチン
WO2007084507A2 (en) 2006-01-13 2007-07-26 The Scripps Research Institute [ψ[CH2NH]PG4] GLYCOPEPTIDE ANTIBIOTIC ANALOGS
EP1986665B1 (en) 2006-01-19 2018-05-02 TerraVia Holdings, Inc. Microalgae-derived compositions for improving the health and appearance of skin
US9005682B2 (en) 2006-03-07 2015-04-14 Nestec S.A. Synbiotic mixture
AU2007225549B2 (en) 2006-03-10 2012-09-27 N.V. Nutricia Use of non-digestable sacharides for giving an infant the best start after birth
AR060123A1 (es) 2006-03-23 2008-05-28 Nutricia Nv Formula para prematuros
US20090143301A1 (en) 2006-03-23 2009-06-04 Nestec S.A. High calorie nutritional supplement
US20070255598A1 (en) 2006-03-29 2007-11-01 Mccarthy Nancy J Compliance aid, kits comprising the compliance aid, and methods of use
WO2007114683A1 (en) 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
MX2008015031A (es) 2006-05-26 2008-12-05 Nestec Sa Metodos de uso y composiciones nutritivas de extracto de touchi.
US20080003329A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US8691213B2 (en) 2006-08-04 2014-04-08 SHS International Protein free formula
EP1887017A1 (en) 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
WO2008033520A2 (en) 2006-09-15 2008-03-20 The Regents Of The University Of California Bifidobacterial gene sequences and their use
US20080089981A1 (en) 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
US20100063002A1 (en) 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
NL1033698C2 (nl) 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
WO2008139984A1 (en) 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
CA2698374C (en) 2007-09-07 2018-04-03 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
JP2009075285A (ja) 2007-09-20 2009-04-09 Fujifilm Corp 半導体デバイスの剥離液、及び、剥離方法
US10251899B2 (en) 2007-10-08 2019-04-09 Mead Johnson Nutrition Company Method for improving stool characteristics in infants
US20090118229A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
AU2008324105B2 (en) 2007-11-08 2014-01-30 Société des Produits Nestlé S.A. Use of oligosaccharides containing N-acetyllactosamine for maturation of immune responses in neonates
WO2009067000A1 (en) 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
WO2009102193A1 (en) 2008-02-12 2009-08-20 N.V. Nutricia A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
NL2001377C2 (nl) * 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
BRPI0822485A2 (pt) 2008-03-18 2015-06-16 Aleksander Vladimirovich Dikovskiy Composição farmacêutica para prevenção de disbiose associada com administração enteral de antibióticos.
EP2127661A1 (en) 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
GB0809921D0 (en) 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
WO2010023178A1 (en) 2008-08-28 2010-03-04 Chr. Hansen A/S Pharmaceuticals comprising a bacterial polysaccharide
EP2370084B1 (en) 2008-12-02 2014-10-22 Prolacta Bioscience, Inc. Human milk permeate compositions and methods of making and using same
MY183602A (en) 2008-12-19 2021-03-02 Chr Hansen Hmo Gmbh Synthesis of fucosylated compounds
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
EP2405918B2 (en) 2009-03-13 2020-09-02 The Regents of The University of California Prebiotic oligosaccharides
WO2010115935A1 (en) 2009-04-07 2010-10-14 Glycom A/S Synthesis of 2 ' -o-fucosyllactose
PT2429539T (pt) 2009-05-11 2017-01-12 Nestec Sa Lactobacilos johnsonii la1 ncc533 não replicativo (cncm i-1225) e distúrbios imunitários
TWI381845B (zh) 2009-05-21 2013-01-11 Univ Nat Taiwan 預防和治療幽門螺旋桿菌感染的組成物
CA2767043C (en) 2009-07-06 2020-07-14 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
EP3342413B1 (en) 2009-07-15 2021-10-20 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing viral diarrhoea
WO2011013106A1 (en) 2009-07-30 2011-02-03 Danisco A/S Lactic acid bacteria and bifidobacteria for treating endotoxemia
US20120121562A1 (en) 2009-07-31 2012-05-17 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
US20110027412A1 (en) 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
WO2011024468A1 (ja) 2009-08-27 2011-03-03 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
BR112012017978A2 (pt) 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
WO2011136636A1 (en) 2010-04-27 2011-11-03 N.V. Nutricia Use of 6'-sialyl lactose in infant nutrition
EP2563165A1 (en) 2010-04-27 2013-03-06 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
WO2012009315A2 (en) 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
EP2455387A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465508A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465507A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2465509A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP3510873A1 (en) 2010-12-31 2019-07-17 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
EP2658402A1 (en) 2010-12-31 2013-11-06 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
NZ612105A (en) 2010-12-31 2015-02-27 Abbott Lab Human milk oligosaccharides for modulating inflammation
CA2822664C (en) 2010-12-31 2021-07-20 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
BR112013016936A2 (pt) 2010-12-31 2019-09-24 Abbott Lab métodos de usar oligossacarídeos de leite humano para melhorar a saúde respiratória das vias aéreas
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EP2658401A2 (en) 2010-12-31 2013-11-06 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US9567361B2 (en) 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
US20130012472A1 (en) 2011-07-05 2013-01-10 Boston College Composition and methods of inhibiting gastrointestinal pathogen infection
EP2734210B1 (en) 2011-07-22 2017-11-22 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MY169326A (en) 2011-08-29 2019-03-21 Abbott Lab Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
ES2666491T3 (es) 2011-10-18 2018-05-04 Nestec S.A. Composición para promover la angiogénesis intestinal, la absorción nutricional y la tolerancia a la alimentación enteral y/o la prevención y/o el tratamiento de las inflamaciones intestinales y/o la recuperación después de las lesiones y/o intervenciones quirúrgicas intestinales
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
DE202013012829U1 (de) 2012-06-14 2020-03-04 Glycom A/S Verbesserung der Stabilität und Reinheit sowie Erhöhung der Bioverfügbarkeit von menschlichen Milch-Oligosacchariden oder Vorläufern oder Mischungen davon
SG10202002010VA (en) 2015-03-13 2020-05-28 Evolve Biosystems Inc Compositions that metabolize or sequester free sugar monomers and uses thereof
RU2725883C2 (ru) 2015-04-23 2020-07-07 Компани Жервэ Данон Композиция для сокращения выработки кишечного газа
ES2879985T3 (es) 2015-08-04 2021-11-23 Nestle Sa Composiciones nutritivas y fórmulas infantiles que comprenden Bifidobacterium animalis ssp. lactis y, opcionalmente, una mezcla de oligosacáridos para inducir una microbiota intestinal cercana a la de bebés alimentados por lactancia materna
US20180303883A1 (en) 2015-10-19 2018-10-25 Meiji Co., Ltd. Anti-allergic agent for infants
US20180311289A1 (en) 2015-10-19 2018-11-01 Meiji Co., Ltd. Infection protective agent for infants
SG11201807809XA (en) 2016-03-11 2018-10-30 Evolve Biosystems Inc A transient commensal microorganism for improving gut health
CA3017371A1 (en) 2016-03-11 2017-09-14 Evolve Biosystems, Inc. Food compositions for weaning
TWI744311B (zh) 2016-04-13 2021-11-01 日商明治股份有限公司 以新生兒為對象的腦功能改善用組成物
GB201611486D0 (en) 2016-06-30 2016-08-17 Promovita Ingredients Ltd Composition for treatment and/or nutrition of poultry
CA3029631A1 (en) 2016-07-01 2018-01-04 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system
US20200315235A1 (en) 2016-10-05 2020-10-08 N. V. Nutricia Normalization of the Intestinal Microbiota Composition in Infants or Toddlers Fed with an Amino Acid-Based Nutritional Composition
WO2018106844A1 (en) 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
WO2018112366A1 (en) 2016-12-15 2018-06-21 The Regents Of The University Of California Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
US20180200312A1 (en) 2017-01-17 2018-07-19 The Regents Of The University Of California Methods and Compositions for Enhancing Memory and/or Reducing Fear and/or Pain of a Host by Administering a Probiotic
KR102089836B1 (ko) 2017-03-15 2020-03-16 (주)바이오일레븐 트립토판분해효소 음성균과 인터페론 감마 형성을 유도하는 균주를 이용한 염증성 질환 예방 및 치료용 약학적 조성물 또는 이를 이용한 치료방법
JP2018177703A (ja) 2017-04-14 2018-11-15 株式会社明治 Ｔｏｌｌ様受容体２活性化用組成物
WO2019000098A1 (en) 2017-06-30 2019-01-03 Wilfrid Laurier University THERMOSIPHON FILLED WITH LIQUID TO A FORCED CIRCULATION PHASE
SG11202002325VA (en) 2017-09-13 2020-04-29 Evolve Biosystems Inc Metabolomic revision of mammalian infants

Also Published As

Publication number Publication date
US20200078385A1 (en) 2020-03-12
BR112013016905A2 (pt) 2019-09-24
US9539269B2 (en) 2017-01-10
US20200093846A1 (en) 2020-03-26
SG10202110501RA (en) 2021-11-29
US11690859B2 (en) 2023-07-04
US20120172319A1 (en) 2012-07-05
SG191392A1 (en) 2013-08-30
MX2013007692A (es) 2013-08-15
CN107019701B (zh) 2020-07-28
EP2658547A1 (en) 2013-11-06
CA2822219C (en) 2020-12-29
WO2012092156A1 (en) 2012-07-05
NZ611807A (en) 2015-02-27
US20170224714A1 (en) 2017-08-10
US10471081B2 (en) 2019-11-12
US20230338404A1 (en) 2023-10-26
US11179406B2 (en) 2021-11-23
MY171620A (en) 2019-10-21
MY197622A (en) 2023-06-28
CN103338775A (zh) 2013-10-02
SG10201603856PA (en) 2016-07-28
MX2020010780A (es) 2020-10-28
CA2822219A1 (en) 2012-07-05
CN107019701A (zh) 2017-08-08

Similar Documents

Publication Publication Date Title
MX2022011064A (es) Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana.
PH12017500874A1 (en) Human milk oligosaccharides for modulating inflammation
MX338174B (es) Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios.
MY169326A (en) Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MY174541A (en) Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
HK1174800A1 (en) Products for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child
MX2021014138A (es) Metodos para usar los oligosacaridos de leche humana para mejorar la salud respiratoria de las vias aereas.
MX352040B (es) Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
EP4382108A3 (en) Synergistic production of butyrate associated with the complexity of hmos blend for use in infants or young children for health purposes
MY191538A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
MX2013007675A (es) Combinacion simbiotica de oligosacaridos probioticos y de leche humana para promover el crecimiento de la microbiota beneficiosa.
MX350782B (es) Galacto-oligosacaridos para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
PH12016500772A1 (en) Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
PH12017500873A1 (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides